Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Novogen — Investor Presentation (April 2013)
18 slides from Kazia Therapeutics's investor presentation, Apr 8, 2013
Slide 1: Form 6-K Report of Foreign Private Issuer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2013 Commission File Number Novogen Limited (Translation of registrant’s name into Eng
Slide 2: Signature
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Novogen Limited (Registrant) Andrew Bursill Andrew Bursill Company Secretary Date 8 April 2013
Slide 3: A new company with new management, Board and technology platform
A new new management Board company with: teamaanew technology platform for cancer drug development a
Slide 4: Disclaimer
This Disclaimer In particular, presentation a. Novogen: does is confidential not warrantand theisaccuracy not an offer or completeness or a recommendation of the information or intendedincluding to influence any you forward in any looking way instatements, making an ifinvestment any, in thisdecision
Slide 5: Company history
Company 3?of1994 1998 2001 2007(GK 2009 2011 2012 otherMEI Novogen NASDAQ Broad Oncology Decision (Nov) (Dec) assets. history/Triaxial leaves MEI Novogen Novogen drug taken Ltd Pharma Marshall Company) technologies(oncology, ASX to acquires divests focus Novogen merger Consumer Edwards itself all Tr
Slide 6: Novogen 4-Gen technology: tested, unique, simple
4•Gen Tested Simple Unique pan tumour?specific unaffected restore 4modest Evidence lead 1cancer technology drug in chemo?sensitivity benzopyran anti?cancer >ofby effect 800 candidates efficacy multi?drug patients platform stem action molecules in late?stage cell resistance activity chemo?refractory
Slide 7: Gen 2 technology: need and challenge
Gen technology Need increase improve new Challenge: 5need 2to to: technology overcome bio?availability potency manufacturing required against design platform efficiencies. both to andcreate manufacturing cancer a new cellsfamily andlimitations. cancer of more stemcomplex cells benzopyrans
Slide 8: Gen 2 technology: super-benzopyrans manufacturing change
Gen 2 technology Manufacturing Change SUPER?BENZOPYRANS Substantial 6COMPREHENSIVE in electrical increase andplatform design in field ANTI?CANCER potency charges breakthrough both increased cancer THERAPY larger, stem bio?availability more cellscomplex and daughter molecules cancer cells
Slide 9: Cancer stem cells and recurrent cancer
Conventional Almost •degree With The Cancer In time, RECURRENT some of all stem the sensitivity forms notable cancer cancer cells of (yellow), human stem exceptions to therapy cancer radiation cells cancer typically however, reproduce (e.g. orare chemotoxic melanoma, isthought are more toalmost crea
Slide 10: Comprehensive anti-cancer therapy
Comprehensive Short ??Comprehensive level 8??It ismulti?drug term ‘comprehensive’ Remission anti?cancer resistance anti?cancer Long?term as itmechanisms. therapy aims therapy to Remission provide refers long?term to the ability remission to kill both of cancer standard through cancer effective cells
Slide 11: In vitro cytotoxicity of super-benzopyran analogs against cancer cell lines
•Standard 20 CS20 CS19 Prostate CS18 CS17 CS16 Colon CS15 CS14 CS13 Glioma CS6 CS5 CS3 Skin Melanoma 0CS2 9In Ability 20 vitro unacceptably Lung 40 A?431 Breast Prostate Colon Glioma HT?29 HCT?15 A172 cytotoxicity U87?MG 60 LNCaP PC3 of cancer A549 H460 A375 80 first SW480 HCT116 MDA?MB?231 MCF7 T98
Slide 12: CS-6 activity against ovarian cancer stem cells
•Active ?g/mlInhibitory 10 CS?6 against is highlycancer effect activestem ofagainst CS?6 cellsovarian on the growth cancerof stem the cell R127 line. ovarian Note cancer that thestem anti?cancer cell line.effect starts at 4 hours and occurs at very low dose rates (2 nanomolar), indicating a highly e
Slide 13: Comprehensive therapy market snapshots
Cancer Drug HER2+ Increase Herceptin 25.1 ??($50,000 Chronic Gleevac ??4500 increase Taxotere 15.3 CS?6 11 months Area Comprehensive therapy cases breast myeloid $$??( from Late?stage ??20?25% Benefit p.a. survival USA 12.7 20.3 cancer 50,000 snapshots treatment leukaemia Market vsprostate all $canc
Slide 14: Company Strategy: CS-6
Company Strategy ?CS?6 ?highly highly ?Novogen ?Ability no their 12 other daughter active isactive to drug Novogen’s Strategy: aims destroy against (currently cancer intothe bring both To first laboratory (ovarian) cells develop cancer approved CS?6 super?benzopyran in a to cancer selective stem the
Slide 15: Securities, share price and major holders
Signature Securities Unlisted issue 117,405,676 6Share Market Cash Number Security Mr Major Funds) 21holders Board Chairman Executive Scientific Non Recent Vol 0.40 20,000 0.35 0.20 015,000 0.05 5,000 Oct As months Price 0.00 Josiah (‘000) 12 Executive 25,000 10,000 at ~$1 price1 Security of Nov12 0
Slide 16: Development milestones
Development Design Achieve Confirm Phase Clinical 14 1aand 1b Pre-Clinical manufacturing acceptable ability Study make milestones tosuper?benzopyran inhibit half?life Fundamentals process tumour of drug producing xeograft molecules growth clean product Determine Design chemo?sensitising analogs with
Slide 17: Funding development
Novogen Funding development ?The enable ?Generate ?Investigate ??Continue ??Working 15 ?Take purpose Novogen CS?6 isthe capital. with currently the plan. of data through potential the to: anCorporate toanalog Pre?clinical capital seeking enable itsclinical pre?clinical program raising the costs to r
Slide 18: Company, stock and contact details
Company Stock Contact Address Website 16 code details For http://www.novogen.com/ Level Novogen NRT investment 1, (ASX), 1?7Limited Waterloo information: NVGNABN: Road (NASDAQ) 37Professor North 063 259 Ryde, 754 Graham NSWKelly 2113, CEO Australia and Chairman [email protected]